A computer-vision guided automated microinjection system with increased robustness, throughput, and generalizability to diverse species

Active Project Grant Awarded Last action

Award ID
R44OD037625
Recipient
Awarding agency
Obligated
$1,200,472

Award facts

Assistance listing
93.351 Research Infrastructure Programs
Completion date 44% complete
Funding agency
Office of the Director National Institutes of Health, Department of Health and Human Services
Place of performance
Minneapolis, MN 55401, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Objective biotechnology is a spin-out from the university of minnesota that is pioneering the use of machine vision guided robots for automating precise procedures such as microinjection. A key challenge in biological research is the bottleneck of generating transgenic and mutant animals. Traditionally, transgenesis and gene editing experiments involve skilled technicians performing intricate and precise microinjection procedures repeatedly. Objective biotechnology INC. Has introduced an innovative solution; a machine vision guided robot designed to automate the microinjection process for drosophila embryos. This technology can also be readily adapted for use with various other organisms. This robot eliminates the need for manual microinjection protocols, which are operator-dependent, time-consuming, and require significant training. The robot uses machine learning (ML) models trained to detect individual embryos on agar plates and guides microinjection needles to perform microinjections at specific locations in each detected embryo. This robot can be operated by individuals with no prior experience and surpass human capabilities in terms of microinjection speed and accuracy. Objective biotechnology was previously awarded an sbir phase I grant to develop a pre-commercial version of the autoinjector. This phase II sbir proposal will build off that work and engineer a fully autonomous microinjection robot for commercial dissemination. In aim 1 of this proposal, we will develop hardware and software to enable the autoinjector to automatically change pipettes when clogging or other issues are detected. This, together with multi-dish capabilities, will also allow experimenters to perform multiplexed experiments where there are multiple constructs that need to be injected within the same injection session. In aim 2 we will robustly test these improvements over the course of more than 500 injection experiments in partnership with drosophila researchers at baylor college of medicine. We will incorporate feedback from this beta testing site to refine and improve the systems developed in aim 1. In aim 3, we will develop software tools to enable users to train new machine learning models to target new species or structures. Accomplishing these aims will provide US with tools that will allow US to access additional markets and optimize the improved instrument for commercial launch at the end of phase II.

Quick answers

Who received award R44OD037625?

R44OD037625 was awarded to Objective Biotechnology, Inc. by Aggregate Financial Assistance Data (National Institutes of Health) on September 1, 2024.

How much is award R44OD037625 worth?

$1,200,472 has been obligated on R44OD037625.

Which agency awarded R44OD037625?

Aggregate Financial Assistance Data (National Institutes of Health) awarded R44OD037625, with funding from Office of the Director (National Institutes of Health).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login